STOCK TITAN

Edgewise Therapeutics Inc - EWTX STOCK NEWS

Welcome to our dedicated news page for Edgewise Therapeutics (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Edgewise Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Edgewise Therapeutics's position in the market.

Rhea-AI Summary
Edgewise Therapeutics, Inc. receives Orphan Drug Designations from the European Medicines Agency for Sevasemten (EDG-5506) in the treatment of Becker and Duchenne Muscular Dystrophies. Sevasemten aims to prevent muscle damage and is in late-stage clinical trials. The designation provides regulatory benefits and market exclusivity for up to 10 years in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics announces positive two-year topline results from the ARCH Open Label Trial of Sevasemten in adults with Becker Muscular Dystrophy, showing stabilization of NSAA scores, significant decreases in muscle damage biomarkers, and favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) presents data on EDG-7500 at ACC.24, highlighting its beneficial effects in preventing diastolic dysfunction in non-obstructive hypertrophic cardiomyopathy. EDG-7500, a first-in-class oral cardiac sarcomere modulator, shows promising results in preclinical studies, offering a novel therapy for HCM patients with options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Rhea-AI Summary
Edgewise Therapeutics, Inc. (EWTX) will present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024. The presentation will be webcast live and accessible for replay. Users are advised to connect early for a timely connection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
conferences
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (EWTX) will present at the Leerink Partners Global Biopharma Conference on March 11, 2024. The presentation will be webcast live and accessible for replay. Users are advised to connect early for a smooth experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
conferences
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (EWTX) will present data on EDG-5506, an investigational therapy for dystrophinopathies at the MDA Conference. Dr. Phan will discuss 12-month data from the ARCH trial. The company will also host an Industry Forum on dystrophic muscle preservation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
Rhea-AI Summary
Edgewise Therapeutics, Inc. (EWTX) reports significant progress in advancing muscle-targeted therapeutics with positive financial results and recent business highlights. The company raised $232M in net proceeds, strengthening its balance sheet. They are focusing on developing EDG-5506 for Becker and Duchenne muscular dystrophy, with ongoing trials showing promising results. They are also working on EDG-7500 for hypertrophic cardiomyopathy, further enhancing their pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) receives FDA Fast Track designation for EDG-5506, an investigational treatment for Duchenne and Becker muscular dystrophy. The drug aims to prevent muscle damage in dystrophinopathies, highlighting the urgent need for new therapeutic options for rare muscle disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share, expecting to generate approximately $240 million. The company plans to use the net proceeds to support various clinical trials and research and development programs, as well as for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.57%
Tags
Rhea-AI Summary
Edgewise Therapeutics, Inc. (EWTX) to Present at 42nd Annual J.P. Morgan Healthcare Conference, Highlights 2023 Accomplishments and 2024 Milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
none
Edgewise Therapeutics Inc

Nasdaq:EWTX

EWTX Rankings

EWTX Stock Data

1.52B
51.74M
0.44%
97.84%
6.15%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Boulder

About EWTX

edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from orbimed.